News
NICE Terminates Appraisal for Tevimbra in NSCLC
NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults.
This is because the company did not provide an evidence submission. The company has confirmed that it does not intend to make a submission for the appraisal because the technology will not be launched in the UK for this indication.
Condition: Non Small Cell Lung Cancer
Type: drug